R. England

AstraZeneca (United Kingdom)

Papers

1

Total Citations

54

H-Index

1

About

R. England is a leading researcher in the field of dendrimer-based drug delivery, with a particular focus on enhancing the cytosolic delivery of nucleic acids. Their most-cited work, a 2023 study on "Precise and systematic end group chemistry modifications on PAMAM and poly(l-lysine) dendrimers to improve cytosolic delivery of mRNA," has garnered 54 citations, underscoring its significance in the rapidly evolving area of mRNA therapeutics. England’s major contribution lies in demonstrating how systematic alterations to dendrimer surface chemistry can overcome key barriers to mRNA delivery, such as endosomal escape and cellular uptake. By engineering precise modifications on both PAMAM and poly(l-lysine) dendrimers, they have provided a tunable platform that improves the efficiency and safety of mRNA-based treatments, with potential applications in vaccines, gene therapy, and protein replacement. This work builds on a broader research focus that combines polymer chemistry, nanotechnology, and molecular biology to address challenges in non-viral gene delivery. England’s research is notable for its systematic approach, offering clear design principles for optimizing dendrimer-based carriers, and has positioned them as a key contributor to advancing next-generation delivery systems for genetic medicines.

Research Focus

Key Achievements

1
H-Index
1
Papers
54
Total Citations
54
Avg Citations/Paper
🏆 Most Cited Paper
Precise and systematic end group chemistry modifications on PAMAM and poly(l-lysine) dendrimers to improve cytosolic delivery of mRNA
54 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: AstraZeneca (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago